ClinicalTrials.gg
RecruitingNCT04460313Updated Oct 27, 2026

Nasopharyngeal Carriage of S. Pneumoniae

An interventional study of nasopharyngeal sample (mandatory) and Stools collection or anorectal swab samples (optional) in Nasopharyngeal Carriage, Children, Only and Antibiotic Resistant Strain, sponsored by Association Clinique Thérapeutique Infantile du val de Marne. Recruiting at 1 site in France. Open to participants aged 4 Months to 15 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Association Clinique Thérapeutique Infantile du val de Marne · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 18 years 9 months after the study started (first participant enrolled Sep 2001, registered Jun 2020).
  • Started Sep 2001; still recruiting 25 years 2 months later.
Updated Oct 27, 2026Results publication addedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
29,360
Allocation
Non-randomized
Ages
4 Months to 15 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 29 studies in Sprains and Strains with a site in France — 7 open to participants now, 8 under way, none of them phase 3. Sprains and Strains · France.

Planned enrollment
Largest of 13
29,360 · median 64
Started
2001
the only one that year
No phase
11 of 29
2 open now
Registered
15th of 29
by date
Lead sponsor
2 of 29
Association Clinique Thérapeutique Infantile du val de Marne

Among the 29 studies in Sprains and Strains with a site in France, this one has the largest planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2001, is one of 11 with no phase, and was the 15th registered.

Sprains and Strains

246 studies on the registry are indexed under Sprains and Strains; 49 are open to participants now.

Browse Sprains and Strains studies →

Open to participants now

7 of the 29 studies in Sprains and Strains with a site in France are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 36 Sprains and Strains studies recruiting now, 13 (36%) set no upper age limit and 20 (56%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 4 Months to 15 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Sprains and Strains with a site in France, or all of them as a file.
02

Study summary

This nasopharyngeal (NP) carriage surveillance study was requested by the European Agency for the Evaluation of Medicinal Products as a post-licensing commitment to determine whether the use of the pneumococcal conjugate vaccines (PCVs) including 7 then 13 valents (introduced in 2001 and 2010, respectively) caused a shift in the distribution of Streptococcus pneumoniae serotypes in children with acute otitis media and modified the resistance of this bacterial species to antibiotics.

Read the detailed description

Since September 2001, 66 pediatricians from the ACTIV research and teaching network throughout France participate in this prospective study. Each year from October to June, children of both sexes aged 4 to 36 months, presenting with suppurative acute otitis media (AOM) accompanied by fever and/or otalgia (to increase the probability of pneumococcal AOM), are enrolled. Within this cohort, patients are offered an additional, optional nasal swab for a rapid viral diagnostic test (targeting SARS-CoV-2, RSV, Influenza A, Influenza B, and hMPV).

Additionally, another group of healthy children aged 4 months to 15 years is also enrolled for the main study.

For the ancillary study, a subgroup of children with AOM (aged 6 to 24 months) is enrolled for the assessment of ESBL-producing E. coli resistance.

03

Conditions studied

  • Nasopharyngeal Carriage
  • Children, Only
  • Antibiotic Resistant Strain

Browse trials for

Keywords

  • Pneumococcal conjugate vaccine
  • Streptococcus pneumoniae
  • Carriage
04

Who can participate

The criteria were revised on the registry on Oct 27, 2026. See what changed

Ages eligible
4 Months to 15 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

children seen on an outpatient

Inclusion criteria

Inclusion Criteria:

  • both sexes
  • suffering from suppurative AOM or healthy children

    • age: 4 months to 36 months for AOM
    • age: 4 months to 15 years for healthy children
  • from parents or guardians
  • Children who haven't received antibiotic treatment within 7 days before enrollment,

Exclusion criteria

Exclusion Criteria:

  • severe underlying disease,
  • inclusion in the study during the previous 12 months
  • Children with bullous myringitis cannot be included.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
29,360 participants (estimated)

Study arms

  • Other
    prospective cohort: Main study

    2100 children aged 4 to 36 months with AOM and 1500 healthy control children aged 4 months to 15 years will be enrolled. A mandatory nasopharyngeal swab is planned for these groups.

    Other: nasopharyngeal sample (mandatory)

  • Other
    ESBL cohort- Ancillary study

    For a subgroup of approximately 1500 children with AOM, aged 6 to 24 months, optional stool or anorectal swab samples will be collected.

    Other: nasopharyngeal sample (mandatory) · Other: Stools collection or anorectal swab samples (optional) · Other: nasopharyngeal sample (optional)

  • Other
    Optional Nasopharyngeal sample

    For a subgroup of 1680 children with AOM, an optional nasal sample will be collected to assess the association of various respiratory viruses (SARS-CoV-2, RSV, Influenza A, Influenza B, hMPV) with different pneumococcal serotypes.

    Other: nasopharyngeal sample (mandatory) · Other: nasopharyngeal sample (optional)

Interventions

  • Othernasopharyngeal sample (mandatory)

    A mandatory nasopharyngeal swab is planned for each included patient: patients aged 4 to 36 months with AOM and control children (healthy) aged 4 months to 15 years. The bacteriological analyses will be carried out by the French National Reference Centre for Pneumococci.

  • OtherStools collection or anorectal swab samples (optional)

    For a subgroup of AOM children aged 6 to 24 months, stools samples or anorectal swab samples were collected for assessment of E. coli (ESBL) resistance

  • Othernasopharyngeal sample (optional)

    Optional nasopharyngeal swabs from children with AOM aged 4 to 36 months to assess the association of various respiratory viruses (SARS-CoV-2, RSV, Influenza A, Influenza B, hMPV) with different pneumococcal serotypes.

06

What researchers measure

Primary outcomes

  1. S. Pneumoniae colonisation

    Percentage of children colonised by S. Pneumoniae

    Time frame: at inclusion

  2. S. Pneumoniae colonisation involving to vaccine serotypes

    Percentage of children colonised by vaccine serotypes

    Time frame: at inclusion

  3. S. Pneumoniae colonisation involving to non vaccine serotypes

    Percentage of children colonised by non vaccine serotypes

    Time frame: at inclusion

  4. Reduced of sensitivity to penicillin

    Percentage of Sp carriers with reduced sensitivity to penicillin

    Time frame: at inclusion

  5. Detect the emergence of new serotypes

    Percentage of emerging serotypes detected (\> 10 Percent of isolated Sp, 5 percent of carrier children)

    Time frame: at inclusion

  6. Association of Pneumococcal Serotypes with Respiratory Viruses

    Percentage of pneumococcal serotypes associated with various respiratory viruses (SARS-CoV-2, RSV, Influenza A, Influenza B, hMPV) in children with AOM.

    Time frame: at inclusion

Secondary outcomes

  1. Detect the emergence of resistance S. pneumoniae

    Percentage of penicillin resistant S. pneumoniae

    Time frame: at inclusion

  2. Evaluation of nasopharyngeal carriage of other bacteria

    Assessment of carriage of Haemophilus influenzae, Moraxella Catarrhalis, Staphylococcus aureus and group A Streptococcus in AOM group and in healthy children group.

    Time frame: at inclusion

  3. For the ancillary study, the resistance of E. coli (ESBL) will be evaluated.

    Assessment of E. coli (ESBL) resistance.

    Time frame: at inclusion

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Ouldali N, Cohen R, Levy C, Gelbert-Baudino N, Seror E, Corrard F, Vie Le Sage F, Michot AS, Romain O, Bechet S, Bonacorsi S, Angoulvant F, Varon E. Pneumococcal susceptibility to antibiotics in carriage: a 17 year time series analysis of the adaptive evolution of non-vaccine emerging serotypes to a new selective pressure environment. J Antimicrob Chemother. 2019 Oct 1;74(10):3077-3086. doi: 10.1093/jac/dkz281. PubMed 31280295 ↗
  • Rybak A, Levy C, Bonacorsi S, Bechet S, Vie le Sage F, Elbez A, Varon E, Cohen R. Antibiotic Resistance of Potential Otopathogens Isolated From Nasopharyngeal Flora of Children With Acute Otitis Media Before, During and After Pneumococcal Conjugate Vaccines Implementation. Pediatr Infect Dis J. 2018 Mar;37(3):e72-e78. doi: 10.1097/INF.0000000000001862. PubMed 29227464 ↗
  • Birgy A, Bidet P, Levy C, Sobral E, Cohen R, Bonacorsi S. CTX-M-27-Producing Escherichia coli of Sequence Type 131 and Clade C1-M27, France. Emerg Infect Dis. 2017 May;23(5):885. doi: 10.3201/eid2305.161865. No abstract available. PubMed 28418829 ↗
  • Cohen R, Varon E, Doit C, Schlemmer C, Romain O, Thollot F, Bechet S, Bonacorsi S, Levy C. A 13-year survey of pneumococcal nasopharyngeal carriage in children with acute otitis media following PCV7 and PCV13 implementation. Vaccine. 2015 Sep 22;33(39):5118-26. doi: 10.1016/j.vaccine.2015.08.010. Epub 2015 Aug 11. PubMed 26271823 ↗
  • Cohen R, Levy C, Bonnet E, Thollot F, Boucherat M, Fritzell B, Derkx V, Bingen E, Varon E. Risk factors for serotype 19A carriage after introduction of 7-valent pneumococcal vaccination. BMC Infect Dis. 2011 Apr 18;11:95. doi: 10.1186/1471-2334-11-95. PubMed 21501471 ↗
  • Cohen R, Bingen E, Levy C, Thollot F, Boucherat M, Derkx V, Varon E. Nasopharyngeal flora in children with acute otitis media before and after implementation of 7 valent pneumococcal conjugate vaccine in France. BMC Infect Dis. 2012 Mar 7;12:52. doi: 10.1186/1471-2334-12-52. PubMed 22397629 ↗
  • Levy C, Vie le Sage F, Varon E, Chalumeau M, Grimprel E, Cohen R. Pediatric Ambulatory and Hospital Networks for Surveillance and Clinical Epidemiology of Community-Acquired Infections. J Pediatr. 2018 Mar;194:269-270.e2. doi: 10.1016/j.jpeds.2017.11.050. Epub 2018 Feb 22. No abstract available. PubMed 29637893 ↗
  • Vermee Q, Cohen R, Hays C, Varon E, Bonacorsi S, Bechet S, Thollot F, Corrard F, Poyart C, Levy C, Raymond J. Biofilm production by Haemophilus influenzae and Streptococcus pneumoniae isolated from the nasopharynx of children with acute otitis media. BMC Infect Dis. 2019 Jan 11;19(1):44. doi: 10.1186/s12879-018-3657-9. PubMed 30634919 ↗
  • Birgy A, Madhi F, Jung C, Levy C, Cointe A, Bidet P, Hobson CA, Bechet S, Sobral E, Vuthien H, Ferroni A, Aberrane S, Cuzon G, Beraud L, Gajdos V, Launay E, Pinquier D, Haas H, Desmarest M, Dommergues MA, Cohen R, Bonacorsi S; Group of the National Observatory of Urinary tract Infection due to ESBL-producing Enterobacteriaceae in children. Diversity and trends in population structure of ESBL-producing Enterobacteriaceae in febrile urinary tract infections in children in France from 2014 to 2017. J Antimicrob Chemother. 2020 Jan 1;75(1):96-105. doi: 10.1093/jac/dkz423. PubMed 31617912 ↗
  • Mizrahi A, Cohen R, Varon E, Bonacorsi S, Bechet S, Poyart C, Levy C, Raymond J. Non typable-Haemophilus influenzae biofilm formation and acute otitis media. BMC Infect Dis. 2014 Jul 19;14:400. doi: 10.1186/1471-2334-14-400. PubMed 25037572 ↗
  • Birgy A, Levy C, Bidet P, Thollot F, Derkx V, Bechet S, Mariani-Kurkdjian P, Cohen R, Bonacorsi S. ESBL-producing Escherichia coli ST131 versus non-ST131: evolution and risk factors of carriage among French children in the community between 2010 and 2015. J Antimicrob Chemother. 2016 Oct;71(10):2949-56. doi: 10.1093/jac/dkw219. Epub 2016 Jun 20. PubMed 27330068 ↗
  • Hau I, Levy C, Caeymaex L, Cohen R. Impact of pneumococcal conjugate vaccines on microbial epidemiology and clinical outcomes of acute otitis media. Paediatr Drugs. 2014 Feb;16(1):1-12. doi: 10.1007/s40272-013-0044-2. PubMed 23963858 ↗
  • Birgy A, Cohen R, Levy C, Bidet P, Courroux C, Benani M, Thollot F, Bingen E. Community faecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae in French children. BMC Infect Dis. 2012 Nov 21;12:315. doi: 10.1186/1471-2334-12-315. PubMed 23171127 ↗
  • Caeymaex L, Varon E, Levy C, Bechet S, Derkx V, Desvignes V, Doit C, Cohen R. Characteristics and outcomes of acute otitis media in children carrying streptococcus pneumoniae or haemophilus influenzae in their nasopharynx as a single otopathogen after introduction of the heptavalent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2014 May;33(5):533-6. doi: 10.1097/INF.0000000000000213. PubMed 24263220 ↗
  • Cohen R, Levy C, Bingen E, Koskas M, Nave I, Varon E. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr Infect Dis J. 2012 Mar;31(3):297-301. doi: 10.1097/INF.0b013e318247ef84. PubMed 22330166 ↗
  • Cohen R, Levy C, Bingen E, Bechet S, Derkx V, Werner A, Koskas M, Varon E. [Nasopharyngeal carriage of children 6 to 60 months during the implementation of the 13-valent pneumococcal conjugate vaccine]. Arch Pediatr. 2012 Oct;19(10):1132-9. doi: 10.1016/j.arcped.2012.07.013. Epub 2012 Aug 24. French. PubMed 22925540 ↗
  • Cohen R, Levy C, Thollot F, de La Rocque F, Koskas M, Bonnet E, Fritzell B, Varon E. Pneumococcal conjugate vaccine does not influence Staphylococcus aureus carriage in young children with acute otitis media. Clin Infect Dis. 2007 Dec 15;45(12):1583-7. doi: 10.1086/523734. PubMed 18190319 ↗
  • Cohen R, Levy C, de La Rocque F, Gelbert N, Wollner A, Fritzell B, Bonnet E, Tetelboum R, Varon E. Impact of pneumococcal conjugate vaccine and of reduction of antibiotic use on nasopharyngeal carriage of nonsusceptible pneumococci in children with acute otitis media. Pediatr Infect Dis J. 2006 Nov;25(11):1001-7. doi: 10.1097/01.inf.0000243163.85163.a8. PubMed 17072121 ↗
  • Levy C, Varon E, Bechet S, Bonacorsi S, Cohen R. Similarities and Differences Between Countries When Estimating the Effect of Higher-valency Pneumococcal Conjugate Vaccines on Colonization and Acute Otitis Media. Pediatr Infect Dis J. 2025 May 1;44(5):e184-e186. doi: 10.1097/INF.0000000000004686. Epub 2025 Jan 21. No abstract available. PubMed 39841925 ↗
  • Assad Z, Cohen R, Varon E, Levy C, Bechet S, Corrard F, Werner A, Ouldali N, Bonacorsi S, Rybak A. Antibiotic Resistance of Haemophilus influenzae in Nasopharyngeal Carriage of Children with Acute Otitis Media and in Middle Ear Fluid from Otorrhea. Antibiotics (Basel). 2023 Nov 8;12(11):1605. doi: 10.3390/antibiotics12111605. PubMed 37998807 ↗
  • Cohen R, Bidet P, Varon E, Bechet S, Cohen JF, Bonacorsi S, Levy C. Unprecedentedly high rates of Group A Streptococcus nasopharyngeal carriage in infants and toddlers in France, 2022-2023. Infect Dis Now. 2023 Aug;53(5):104720. doi: 10.1016/j.idnow.2023.104720. Epub 2023 May 15. No abstract available. PubMed 37196808 ↗
  • Rybak A, Levy C, Ouldali N, Bonacorsi S, Bechet S, Delobbe JF, Batard C, Donikian I, Goldrey M, Assouline J, Cohen R, Varon E. Dynamics of Antibiotic Resistance of Streptococcus pneumoniae in France: A Pediatric Prospective Nasopharyngeal Carriage Study from 2001 to 2022. Antibiotics (Basel). 2023 Jun 6;12(6):1020. doi: 10.3390/antibiotics12061020. PubMed 37370339 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2001 (actual). Primary completion is estimated for Dec 2029, 339 months after the start.

Of 80 non-industry interventional studies with no phase under Sprains and Strains, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 35. This study's planned 339 months is above that.

Counting every sponsor, half of 82 studies reached it within 12 months; a quarter within 4 and three quarters within 35.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Dec 2026 → Dec 2029 and completion Dec 2026 → Dec 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2020
First posted
Jul 7, 2020
StartActual
Sep 11, 2001
Primary completionEst.
Dec 31, 2029was Dec 2026
CompletionEst.
Dec 31, 2029was Dec 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2026→Dec 31, 2029
Oct 27, 2026
Study completion
Dec 31, 2026→Dec 31, 2029
Oct 27, 2026
Enrollment
25760→29360
Oct 27, 2026
Eligibility
Minimum age 6 Months→4 Months; 2 inclusion criteria edited
What changed in the criteria
Inclusion criteria
  • Editedage: 64 months to 36 months for AOM
  • Editedage: 64 months to 15 years for healthy children
Oct 27, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionAssociation of Pneumococcal Serotypes with Respiratory Viruses: how it is measured was reworded
Oct 27, 2026
Publications
Results publication added: Cohen R, Bidet P, Varon E, Bechet S, Cohen JF, Bonacorsi S, Levy C. Unprecedentedly high rates of Group A Streptococcus nasopharyngeal carriage in infants and… PubMed 37196808 ↗; 1 more
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Publications Results publication added: Cohen R, Bidet P, Varon E, Bechet S, Cohen JF, Bonacorsi S, Levy C. Unprecedentedly high rates of Group A Streptococcus nasopharyngeal carriage in infants and… PubMed 37196808 ↗; 1 more
    Primary completion Dec 31, 2026→Dec 31, 2029
    Study completion Dec 31, 2026→Dec 31, 2029
    Enrollment 25760→29360
    Eligibility Minimum age 6 Months→4 Months; 2 inclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • Editedage: 64 months to 36 months for AOM
    • Editedage: 64 months to 15 years for healthy children
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionAssociation of Pneumococcal Serotypes with Respiratory Viruses: how it is measured was reworded
    + 3 other changes: verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04460313
Lead sponsor
Association Clinique Thérapeutique Infantile du val de Marne
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Jul 7, 2020
Start date
Sep 11, 2001
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Oct 27, 2026

Study contacts

Corinne Levy, MD
Contact
corinne.levy@activ-france.fr
0033148850404
Stéphane Béchet, MsC
Contact
stephane.bechet@activ-france.fr
0033148850404
Robert Cohen, MD
principal investigator · Association Clinique Thérapeutique Infantile du val de Marne

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion